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Available online 13 August 2016The European Union Council Recommendation of 2 December 2003 on cancer screening suggests the implemen-
tation of organised, population-based breast cancer screening programmes based onmammography every other
year for women aged 50 to 69 years, ensuring equal access to screening, taking into account potential needs for
targeting particular socioeconomic groups. A European survey on coverage and participation, and key
organisational and policy characteristics of the programmes, targeting years 2010 and 2014, was undertaken
in 2014. Overall, 27 countries contributed to this survey, 26 of the 28 European Union member states (92.9%)
plus Norway. In 2014, 25 countries reported an ongoing population-based programme, one country reported a
pilot programme and another was planning a pilot. In eight countries, the target age range was broader than
that proposed by the Council Recommendation, and in three countries the full range was not covered. Fifteen
countries reported not reaching some vulnerable populations, such as immigrants, prisoners and people without
health insurance, while 22 reported that participation was periodically monitored by socioeconomic variables
(e.g. age and territory). Organised, population-based breast cancer screening programmes based on routine
mammograms are in place in most EU member states. However, there are still differences in the way screening
programmes are implemented, and participation by vulnerable populations should be encouraged.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Europe1. Introduction
Breast cancer screening programmes in Europe have been in place
since the late 1980s, since results of trials on their effectiveness became
available (Shapiro, 1977; Tabár et al., 1985; Andersson et al., 1988;ctorate-General for Health and
stat European health interview
on Cancer; EPAAC, European
ación para el Fomento de la
t Valenciana; JRC, European
ectorate General Joint Research
ference Materials, Via E. Fermi
drea).
. This is an open access article underRoberts et al., 1990; Tabár et al., 1992). Surveys conducted in subsequent
years (Jensen et al., 1990; Shapiro et al., 1998; Klabunde et al., 2002;
Lynge et al., 2003; Yankaskas et al., 2004; Broeders et al., 2005;
Klabunde and Ballard-Barbash, 2007) reported a gradual implementation
of programmes, sometimes applying different policies, and heteroge-
neous compliance. At European Union level, the Council Recommenda-
tion of 2 December 2003 (Council of the European Union, 2003) (OJ L
327, 16.12.2003, p. 34.) set a list of requirements for the implementation
of organised, population-based breast cancer screening programmes; it
represents a shared commitment bymember states to implement cancer
screening programmes. The Council Recommendation also recom-
mended a breast cancer screening protocol ‘foreseeing mammography
screening for breast cancer in women aged 50 to 69 in accordance
with European guidelines for quality assurance in mammography’.
The expected outcome of cancer screening programmes is a de-
crease in mortality rates for some types of cancer (von Karsa et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
251S. Deandrea et al. / Preventive Medicine 91 (2016) 250–2632008); however, participation in such programmes is key to attaining
the expected outcomes. The different barriers to participation include:
organisational aspects of the screening programmes; people's knowl-
edge, beliefs and attitudes about the disease and the programmes; and
lack of screening opportunities in some regions of Europe (Bastos et
al., 2010). Together, these barriers are shaping inequalities in cancer
care.
Social inequalities in cancer imply health inequities spanning the full
cancer continuum and cover social inequalities in the prevention, inci-
dence, prevalence, detection and treatment, survival, mortality, and
burden of cancer and other cancer-related health conditions and behav-
iours (Krieger, 2005). Population-based screening programmes assure
more equity in access in comparison with other health initiatives such
as opportunistic screening programmes (Palència et al., 2010). Howev-
er, social inequalities in access can still be observed in population-based
programmes (Spadea et al., 2010), as shown by the fact that vulnerable
populations – those who “because of shared social characteristics are at
higher risk of risks” (Frohlich and Potvin, 2008) — participate less in
breast cancer screening programmes. These groups include those with
lower socioeconomic status, and those pertaining to minority ethnic
groups (von Euler-Chelpin et al., 2008; Szczepura et al., 2008). Equity
aspects are considered in the Council Recommendation, which ask for
‘action to be taken to ensure equal access to screening, taking due ac-
count of the possible need to target particular socioeconomic groups’
(Council of the European Union, 2003).
In 2008, a ﬁrst report of the implementation of the Council Recom-
mendationwas issued (von Karsa et al., 2008) (hereinafter Implementa-
tion Report). It was based on a written survey involving the EUmember
states, conducted by the European Commission's Directorate-General
for Health and Food Safety (DG SANTE) in the second half of 2007,
and complemented by information obtained from two European pro-
jects (European Cancer Network – ECN, and European Network for In-
formation on Cancer – EUNICE). The Implementation Report stated that
most member states had followed the Council Recommendation, and
that most of them intended to undertake future actions. Data collected
through EUNICE, also published by Giordano et al. (Giordano et al.,
2012) in 2012, referred mostly to 2005, 2006 and 2007. In 2010, the
ﬁrst wave of the Eurostat European health interview survey (EHIS)
(Eurostat, 2010) asked for few variables related to cancer screening
(percentage of women who had undergone a mammography and, if a
woman had undergone a mammography, what her reasons for doing
sowere);most countries reported data up to 2008 or 2009.While a sec-
ond Implementation Report is in preparation (DG SANTE Grant Agree-
ment 2011 53 03), no consistent data were available after 2010. In
2014 a new survey was undertaken in order to provide bridging on
some general indicators on breast cancer screening programmes in Eu-
rope, and to provide original data on equity of access to those
programmes.
2. Methods
Contactswithin eachmember statewere derived from two indepen-
dent surveys conducted by the European Commission's Joint Research
Centre (JRC) in 2012 (European Commission Initiative on Breast
Cancer, 2015; Lerda et al., 2014), and the Fundación para el Fomento de
la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
(FISABIO) within the European Partnership for Action Against Cancer
(EPAAC) framework. Further details on those surveys are reported in
Appendix A.
2.1. Data collection
Contributors to the two previous surveys received a joint communi-
cation from the JRC and FISABIO in July 2014, asking if they were inter-
ested in providing data for the publication of a common research paper.
Each country was asked to provide a unique contact person and thenames of up to two additional contributors (with the exception of coun-
tries with regional screening programmes, which were allowed more
contributors). These personswere held responsible for checking and in-
tegrating the information reported in the past two survey(s) they had
contributed to, according to standardised deﬁnitions provided in a
new questionnaire. Deﬁnitions from the EUNICE project (EUNICE,
2012) and the Implementation Report (von Karsa et al., 2008) were ap-
plied when relevant. All countries except one that had participated in
previous surveys agreed to contribute to the new paper.
2.2. Data analysis
A descriptive study of the main variables included in the question-
naire was performed. Calculations for the total number of women in
the eligible population, total number of women invited and total num-
ber of women screened only considered the data available for the coun-
tries/regions providing information. Coverage by invitation, coverage by
test, and participation rate were computed using EUNICE's formulas for
an annual period (EUNICE, 2012). Coveragewas deﬁned as the extent to
which the screening programme covers the eligible population within
the appropriate interval in a given period by invitation (invitation
coverage), and the extent to which the screening programme covers
the eligible population with screening tests (examination coverage).
Coverage by invitation was calculated as the annual number of invita-
tions divided by the annual target population; coverage by test was cal-
culated as the annual number ofwomen screened divided by the annual
target population. Participation is deﬁned as the proportion of women
personally invited for screening who actually attended, and was calcu-
lated by dividing the annual number of women screened by the annual
number of invitations.
3. Results
3.1. Respondents
Twenty-seven countries contributed to this survey, 26 of the 28
member states (92.9%) (no data from Greece or Slovakia) plus Norway.
Data covering the whole state was provided by all the surveyed states,
with the exception of United Kingdom (England only), Portugal (four
regions out of seven), and Spain (15 regions out of 19). All the countries
contributed both information for 2010 and 2014 about the screening or-
ganisation and protocol; regarding performance indicators, 20 countries
contributed with 2014 data, three with 2013, three with 2012 and one
with 2011. On inequality issues, all countries reported data for the
2010–2014 period except Romania (its programme began in 2014). In-
formation on interventions to tackle inequalities was provided sepa-
rately for the 2007–2012 and 2012–2014 periods.
3.2. General characteristics
General information on screening policy is reported in Table 1, Table
2 and Fig. 1. Most screening programmes started in the ﬁrst decade of
this century, with the exception of Sweden (1985), Finland (1987), En-
gland (1988), the Netherlands (1990), Denmark (1992), Luxembourg
(1992), Norway (1996) and more recently Austria (2010) and Bulgaria
(2013) [data not shown]. By 2010, 20 countries had rolled-out a popu-
lation-based programme (in Portugal only for the Central Region,
Alentejo and Algarve); in 3 countries (Malta, Poland and Slovenia), as
well as for the Northern Region of Portugal, the rollout was ongoing.
In three countries the programmewas in its pilot (Austria, CzechRepub-
lic) or planning (Bulgaria) phase. In 2014, Malta and Poland completed
the rollout, Bulgaria started a pilot and Romania initiated planning,
which corresponds to 24 countries having a fully implemented popula-
tion-based breast cancer screening programme. In 2014, a national
programme or a regional programme with national coordination
(Denmark, Portugal) was present in all countries; only Belgium
Table 1
Breast cancer screening programmes in 2010 and 2014.
Programme type:
NP = Non-programme screening. Examinations for early detection of breast cancer performed in a diagnostic or clinical setting, independent from the public screening policy
P= Programme screening. Examinationsﬁnanced by public sources performed in the context of a public screening policy documented in a law, or an ofﬁcial regulation, decision, directive
or recommendation, and where the policy deﬁnes, at minimum: the screening test, the examination intervals, group of persons eligible to be screened
O=Organised screening. Programme screeningwhere other procedures (e.g. standard operatingprocedures) are speciﬁed andwhere a team at national or regional level is responsible for
implementing the policy
PB= Population-based screening. Programme screening where in each round of the screening the persons in the eligible target area served by the programme are individually identiﬁed
and personally invited
NA = Not applicable
Coordination: NS=National screening programme; R/NC=Regional screening programme, nationally coordinated; R= Regional screening programme; L, N/RC= Local screening pro-
gramme, regional/national coordinated; L = Local screening programme; NA = Not applicable
Implementation: Planning phase (PL); Pilot phase (PI); Rollout on-going (RO); Rollout completed (RC)
Type of Test: M =Mammography; CBE = Clinical Breast Examination.
Country Update
period
Programme
type
Coordination Implementation
status
Type of test Age range Interval (months) Notes
Austria
2010 PB L, N/RC PI M Three pilot regions: 50–69,
two pilot regions: 40–69
12/24 months
(depending on pilot
project, age or BIRADS)
2014 PB NS RC M (digital) Personally invited: 45–69;
Via Opt-In – Serviceline
(telephone) or online
(website): 40–44 and 70+
Fixed interval: 24
months; BIRADS III:
early rescreen after 6
or 12 months possible
Belgium
2010 PB R RC M 50–69 24 Important parallel opportunistic
activity ongoing
2014 PB R RC M 50–69 24
Bulgaria
2010 NP
PB
–
NS
–
PL
M NP: over 50
PB: 50–69
NP: 24
PB: 36
NP: funded by the National Health
Insurance fund
Some regional oncological centres
offer prophylactic
mammographies paid by the
municipalities
2014 NP
PB
–
NS
–
PI
M NP: over 50
PB: 50–69
NP: 24
PB: 36
Croatia
2010 O
PB
NS RC M 50–69 24
2014 O
PB
NS RC M 50–69 24
Cyprus 2010 PB NS RC M 50–69 24
2014 PB NS RC M (digital) 50–69 24
Czech
Republic
2010 O
PB
NS RC (O, NS)
PI (PB, NS)
M Over 45 24 PB (centralised invitation), as
currently implemented it is aimed
at women not attending the
screening programme during the
previous three years. The
individuals in the target
population are therefore covered
either by invitation or actual
screening examination
2014 PB NS RC M (digital) Over 45a 24
Denmark
2010 PB R/NC RC M (digital) 50–69 24 Mammography screening started
in Copenhagen Municipality in
1991 followed by the County of
Funen in 1993 and subsequent by
three other counties in
1994–2004. Rollout to rest of the
country took place between 2007
and 2010
2014 PB R/NC RC M (digital) 50–69 24
Estonia 2010 PB NS RC M 50–62 24
2014 PB NS RC M 50–62 24
Finland
2010 PB NS RC M (digital) 50-69b 24c The responsibility to organise
actual breast cancer screening is
given to local municipalities (226
in 2012; 320 in 2013)
2014 PB NS RC M (digital) 50–69b 24
France 2010 PB NS RC M+ CBE 50–74 24
2014 PB NS RC M+ CBE 50–74 24
Germany 2010 PB NS RC M 50–69 24
2014 PB NS RC M (digital) 50–69 24
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Table 1 (continued)
Country Update
period
Programme
type
Coordination Implementation
status
Type of test Age range Interval (months) Notes
Hungary 2010 PB NS RC M 45–65 24
2014 PB NS RC M 45–65 24
Ireland
2010 PB NS RC M 50–64 24 From 2015 Ireland will commence
extending breast screening from
65 to 69 year olds. This will be
completed by 2021
2014 PB NS RC M 50–64 24
Italy 2010 PB NS RC M 50–69 24
2014 PB NS RC M 50–69 standard protocol
45/49–69d
50–74e
24
12 for 45–49 years old
Latvia 2010 PB NS RC M 50–69 24
2014 PB NS RC M 50–69 24
Lithuania
2010 PB NS RC M 50–69 24 The pilot programme started in
1999, it was expanded to the
whole country in 2005
2014 PB NS RC M 50–69 24
Luxembourg 2010 PB NS RC M 50–69 24
2014 PB NS RC M (digital) 50–69 24
Malta 2010 PB NS RO M 52–60 36
2014 PB NS RC M 50–60 36
Netherlands 2010 PB NS RC M 50–75 24
2014 PB NS RC M 50–75 24
Norway 2010 PB NS RC M (digital) 50–69 24
2014 PB NS RC M (digital) 50–69 24
Poland
2010 PB NS ROf M 50–69 24 Population based pilot phase of
screening was performed in 2006
2014 PB NS RC M
(screen-ﬁlm
and digital)
50–69 24
Portugal
2010 PB R/NC Central region,
Alentejo and
Algarve: RC
North Region:
RO
M (digital)g 45-69g
50-69h
24 Four regions contributed to the
survey: Alentejo, Algarve, Central
Region, Norte
2014 PB R/NC Central region,
Alentejo and
Algarve: RC
North Region:
RO
M (digital)g 45-69g
50-69h
24
Romania
2010 Not present
in 2010
– – – – – Breast Cancer Screening pilot was
ﬁnally signed to be ﬁnanced by
Ministry of Health within R0 19
Norwegian Funds in December
2014
2014 O R PL M 50–69 24
Slovenia
2010 O
PB
NS RO M 50–69 24 In 2010 coexistence of organised
and opportunistic screening
2014 O
PB
NS RO M 50–69 24
Spain
2010 PB R RC M
(screen-ﬁlm
and digital)
45-69i
50-69j
24 Information for Spain refers to 19
regions
2014 PB R RC M (digital) 45-69i
50-69j
24
Sweden
2010 PB NS RC M 40–74 18–21–24 depending
on age and areak
2014 PB NS RC M 40–74 18–21–24 depending
on age and areak
United
Kingdom
2010 PB NS RC M 50–70 36 Data referring to England only
2014 PB NS RC M 50–70 36
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Table 2
Breast cancer screening programmes in 2010 and 2014, aggregated characteristics.
2010 2014
N (%) N (%)
Programme type Population-based only 22 (81.5) 23 (85.2)
Organised 0 (0.0) 1 (3.7)
Population-based and organised
cohexisting
3 (11.1) 2 (7.4)
Population-based and non
programme cohexisting
1 (3.7) 1 (3.7)
Not applicable 1 (3.7) 0 (0.0)
Coordination National 21 (77.8) 22 (81.5)
Regional/National coordinated 2 (7.4) 2 (7.4)
Regional 2 (7.4) 3 (11.1)
Local/Regional-National
coordinated
1 (3.7) 0 (0.0)
Not applicable 1 (3.7) 0 (0.0)
Implementation status Planning 1 (3.7) 1 (3.7)
Pilot 1 (3.7) 1 (3.7)
Rollout ongoing 3 (11.1) 1 (3.7)
Rollout completed 19 (70.4) 23 (85.2)
Other 1 (3.7) 1 (3.7)
Not applicable 2 (7.4) 0 (0.0)
Type of test Mammography 25 (92.6) 26 (96.3)
Mammography + Clinical breast
examination
1 (3.7) 1 (3.7)
Not applicable 1 (3.7) 0 (0.0)
Age range covereda 50–69b 23 24
Interval (months) 24 21 (77.8) 21 (77.8)
36 3 (11.1) 3 (11.1)
Depending on other variables
(site, age, BIRADS, etc.)
2 (7.4) 3 (11.1)
Not applicable 1 (3.7) 0 (0.0)
a The sum is higher than 27 because each single screening protocol is counted once.
b 50–70 approximated to 50–69.
Fig. 1. Breast cancer screening programmes in 2010 and 2014.
254 S. Deandrea et al. / Preventive Medicine 91 (2016) 250–263(whose performance data are reported separately for Brussels, Flanders
and Wallonia) and Spain had regional screening programmes in place.
The planned project in Romania has regional coordination; Austria
switched from local/national or regional coordination to national coor-
dination between 2010 and 2014. National and regional websites are
listed in Appendix B.
3.3. Screening protocol
The screening method used most often (Table 1 and Table 2) is
mammography alone, with the exception of France, which implements
mammography plus clinical breast examination. A speciﬁc question on
analogic vs. digital mammography was not included in the survey, but
this information was voluntarily reported by some countries. Regarding
the target age, Portugal, Austria, Spain and Italy have different protocols
according to the region.Women have been targeted from at least age 50
in all countries with active programmes since 2010 but Malta; a lower
target age was applied in 7 countries/regions either in 2010 or 2014Notes to Table 1:
a Invitation up to 70.
b Both in years 2010 and 2014 the implementation phase for older ages was ongoing (almost
years. However, according to Government Decree on Screening, since the beginning of year 200
or after that. Thus there has been a gradual implementation of this programme inolder age grou
69 years).
c 20–26 months interval reported in the Government Decree on Screening.
d Piedmont and Emilia Romagna regions.
e Several programmes.
f Lower Silesia only.
g Alentejo, Central Region, Norte.
h Algarve.
i Valenciana, Castilla-La Mancha, Castilla y León, Ceuta, Melilla, Navarra, La Rioja.
j Andalucía, Aragón, Asturias, Baleares, Canarias, Cantabria, Cataluña, Extremadura, Galicia, M
k Inmost places in Sweden youngerwomen are invitedwith 18months interval and older w
the northern part of Sweden, it is not possible to come back for the 18 and 24months interval s
are invited in an interval of 21 months. In Stockholm, since January 2015, all women in the ag(from age 40 or 45 according to the speciﬁc protocol). In 2010, three
countries (France, the Netherlands, Sweden) were inviting the over
70s for screening, a number that increased to ﬁve countries in 2014
with the inclusion of some regions in Italy and Austria. Overall, the tar-
get age speciﬁed in the Council Recommendation (50–69 years) wascomplete in 2014). During years 1987–2006 screeningwas offered for women aged 50–59
7 the upper age of screeningwas increased to 69 years for thosewomen born on year 1947
ps and the full coverageof theprogrammewill be reached by 2016 (for all womenaged 50–
adrid, Murcia, País Vasco.
omenwith 24months interval. But in counties where you have to usemobile units, such as
o all women are invitedwith 24months interval. In the western part of Sweden all women
e group between 40 and 74 will be invited in a 24 months interval.
255S. Deandrea et al. / Preventive Medicine 91 (2016) 250–263adopted as such in 18 countries/regions in 2010 and 2014; in four coun-
tries (Estonia, Hungary, Ireland, Malta) the target age range was not
completely covered in either 2010 or 2014. In 2014 the IrishTable 3
Breast cancer screening programmes in 2010 and last update: coverage by test, coverage by in
Coverage by invitation: annual number of invitations divided by the annual target population.
Coverage by test: the annual number of women screened divided by the annual target populat
Participation: annual number of women screened divided by the annual number of invitations
Country Update period Annual eligible
population
Number of
invitations
Num
scree
Austria 2010 200,000 200,000 27,00
2014 1,500,000 1,500,000 600,0
Belgium
Brussels
2010 52,000 57,802 6194
2014 52,000 55,029 5791
Belgium
Flemish
2010 380,317 370,016 183,3
2014 Not available Not available 204,0
Belgium
Walloon
2010 Not available 218,412 18,16
2014 Not available 238,637 19,01
Bulgaria 2010 1,633,000 Not available Not a
2013–2014 1,057,000 123,647 10,39
Croatia 2010 334,543 334,543 147,5
2014 329,988 301,395 131,4
Cyprus 2010 36,193 35,923 16,28
2014 38,908 42,123 17,32
Czech
Republic
2010 879,496 Not applicable 477,4
2013 878,576 521,187a 538,9
Denmark 2010 Not available 310,000 251,0
2014 Not available 324,000 266,0
Estonia 2010 63,800 53,500 33,50
2014 65,534 60,399 34,08
Finlandb 2010 736,262 316,535 268,3
2012 750,813 342,816 284,4
France 2010 4,545,415c 4,545,415 2,361
2014 4,834,417c 4,834,417 2,520
Germanyd 2010 5,233,114 4,888,368 2,624
2011 5,242,172 4,864,574 2,718
Hungary 2010 Not available 475,000 Not a
– Not available Not available Not a
Ireland 2010 368,967 167,088 120,7
2014 395,416 181,922 138,7
Italy 2010 3,611,500 2,495,599 1,382
2013 3,644,000 2,696,888 1,543
Lithuania 2010 214,000 63,769 60,92
2013 234,228 80,826 80,34
Luxembourg 2010 26,550 26,019 16,12
2014 30,274 29,668 18,36
Latvia 2010 203,336 196,578 38,14
2014 159,223 142,168 51,06
Malta 2010 Not available 11,864 6,456
2014 Not available 15,625 9,329
Netherlands 2010 1,250,000 1,193,347 961,7
2012 1,299,000 1,266,555 1,007
Norway 2010 282,000 270,000 201,0
2014 300,000 289,000 213,0
Poland 2010 2,522,421 2,419,459 945,2
2014 2,668,119 2,749,919 1,207
Portugalf 2010 359,217 352,268 181,8
2014 441,531 434,151 263,2
Romania – – – –
– – – –
Sweden 2010 900,000 900,000 720,0
2014 900,000 900,000 720,0
Slovenia 2010 130,000g
22,000h
12,754h 10,29
2014 135,000g
49,000h
38,175 30,40
Spaini 2010 (from 15
regions
1,911,410 1,911,410 1,365
2012 (from 14
regions)
1,907,507 1,907,507 1,411
United
Kingdom
England
2010 2,124,038 2,302,886 1,728
2014 2,276,200 2,276,200 1,770
TOTALj 2010 27,880,370 24,123,792 14,15
Latest update 29,020,899 26,217,196 15,81Government announcedplans to extend its breast cancer screeningpro-
gramme towomen aged 65–69, commencing in 2015. The screening in-
terval is two years in most countries except for Bulgaria, England andvitation, participation rate.
ion.
.
ber of women
ned
Coverage by invitation
(%)
Coverage by test
(%)
Participation rate
(%)
0 100.0 13.5 13.5
00 100.0 40.0 40.0
111.2 12.0 10.7
105.8 11.1 10.5
84 97.3 48.2 48.2
82 Not available Not available Not available
1 Not available Not available 8.3
2 Not available Not available 8.0
vailable Not available Not available Not available
2 11.7 1.0 8.4
25 100.0 45.0 57.0
55 91.0 44.0 60.1
6 99.3 45.3 45.3
6 108.2 44.5 41.1
13 Not applicable 54.3 Not applicable
97 28.7a 61.3 13.4a
00 Not available Not available 81.0
00 Not available Not available 82.1
2 83.9 52.5 62.6
9 92.1 52.0 56.4
14 85.7 72.6 84.8
33 90.9 75.5 83.0
,548 100.0 52.0 52.0
,980 100.0 52.1 52.1
,669 93.4 50.2 53.7
,225 92.8 51.9 55.9
vailable Not available Not available Not available
vailable Not available Not available Not available
30 45.3 32.7 72.3
70 43.5 32.9 75.6
,450 69.1 38.3 55.4
,889 74.0 42.4 57.2
5 Not applicablee 28.5 Not applicablee
8 Not applicablee 34.3 Not applicablee
2 98.0 60.7 62.0
2 98.0 60.6 61.9
8 96.7 18.8 19.4
0 89.3 32.1 35.9
Not available Not available 54.4
Not available Not available 59.7
65 95.5 76.9 80.8
,966 97.5 77.6 80.0
00 95.7 71.3 74.4
00 96.3 71.0 73.7
83 95.9 37.5 39.1
,214 103.1 45.2 43.9
01 98.1 50.6 51.6
44 98.3 59.6 60.6
– – –
– – –
00 100.0 80.0 80.0
00 100.0 80.0 80.0
9h 9.8g
58.0h
7.9g
46.4h
80.8h
5h 28.3g
77.9h
22.5g
62.1h
79.6h
,344 100.0 71.4 71.4
,819 100.0 74.0 74.0
,671 108.4 81.4 75.1
,435 100.0 77.8 77.8
3,224 – – –
6,366 – – –
256 S. Deandrea et al. / Preventive Medicine 91 (2016) 250–263Malta, where it is three years. Two countries adopt a different protocol
according to individual risk: Austria allows early rescreening for BIRADS
III (American College of Radiology, 2013), while some Italian regions in-
vite women between the ages of 45 and 49 every 12 months, and in
Sweden women are invited every 18–21-24 months according to age
and area of residence.
3.4. Coverage by invitation
Table 3 shows the number of women invited and tested each year
per country, as well as the calculated coverage by invitation and partic-
ipation rate, and coverage by test. The number of people invitedper year
depended mostly on the country's population and the programmes'
coverage — ranging from 11864 (Malta, rollout ongoing in 2010) to
~4.800,000 in France and in Germany. The total number of women in
the overall target population that was used to calculate coverage rates
was 28 million in 2010 (data from 23 countries, plus two regions of
Belgium) and 29 million in 2012–2014 (latest annual update from 23
countries, plus one region of Belgium). The total number of invitations
was 24 million in 2010 (data from 24 countries) and 26 million in
2012–2014 (latest annual update from 24 countries, plus two regions
of Belgium). Finally, the number of women screened was 14 million in
2010 (data from 24 countries) and 16 million in 2012–2014 (latest an-
nual update from 25 countries). For some countries the invitation strat-
egy does not include an individual letter and the rates were not
computed in the same way as for the others: in the Czech Republic,
women previously accessed the programme without a personal invita-
tion letter and thosewhohad not previously attendedwere only invited
to do so from 2014; in Lithuania the invitation is sent by the general
practitioner and is registered only when the mammography test is car-
ried out; for Finland, annual coverage by invitation and by test are ap-
proximated, as some municipalities use different invitation schedules
over the two-year round. Coverage by invitation was higher than 90%
in 17 countries, both in 2010 and in 2014.
Comparing coverage by invitation in 2014 with that in 2010, the
greatest increase is observed in countries implementing the rollout
within this period (2010–2014) as opposed to countries that had al-
ready implemented screening before 2010. Signiﬁcant increases were
seen in: Estonia, from 83.9% to 92.1%; Malta, from 55.5% to 100.0%; Slo-
venia: from 9.8% to 28.3%. However, differences among countries and
between 2010 and 2014may be due to differences in the timing of invi-
tations in individual countries.
3.5. Participation rate
As regards the participation rate, in 2010 six countries/regions (Den-
mark, England, Finland, the Netherlands, Sweden and Slovenia) report-
ed a rate above 75%, which is the desirable threshold for the
corresponding indicator in the European Guidelines for quality assurance
in breast cancer screening and diagnosis (hereinafter European Guide-
lines) (Perry et al., 2006). In general, no major differences in individualNotes to Table 3:
a Women previously not attending individually invited Jan–Dec 2014, coverage computed f
b In Finland, some municipalities invite women aged 51–69 years every two years, others in
visits (or tests) must be calculated over a two year period. Thus the coverage of invitation calcu
coverage of the national programme in age group 50–69 in 2010. Additionally, the programme
c Non-adjusted target population.
d The presented data refer to the target population and are derived from the statistical ofﬁce
criteria are not eligible and excluded temporarily: womenwith mammogramwithin the last 1
breast cancer care. Exact adjustment for eligibility as well as complete access to the target pop
e There is no systematic personal invitation system through population register, but via GP's.
the mammography test is done. That is why the numbers of invitations coincide with the num
f Information from 4 regions out of 7 – regional data available on request.
g All country.
h Screening areas.
i Information from 15 regions out of 19 – regional data available on request.
j These ﬁgures only include the sum of the numbers available in each of the cells above.countries' participation rates were observed between 2010 and 2014
formost of those countrieswhere the rollout had already been complet-
ed in 2010. Another three countries (Ireland, Norway and Spain) report
a rate above 70%, which was an acceptable level according to the
European Guidelines. Therefore, there are nine countries with a better
than acceptable level of participation. The latest corresponding ﬁgure
is comparable, with Ireland reaching N75% in 2014. As for the invita-
tions, differences between countries, and between 2010 and 2014 for
individual countries, may be due to differences in the timing of invita-
tions and registration of test uptake.
3.6. Coverage by test
Finally, coverage by test, which depends on the previous indicators,
ranged from7.9% in 2010 (Slovenia, rollout ongoing) to 81.4% (England)
in 2010 and from 1.0% (Bulgaria, pilot) to 80.0% (Sweden) in 2014.
3.7. Equity and access
Inequalities in access were identiﬁed. Although accessing most of
the programmes is free of charge (Table 4) (with the exception of Nor-
way), 16 have programmes that do not cover certain social groups —
most frequently women without health insurance, women without
residence permits, andwomen in prison. Some16programmesdo how-
ever have speciﬁc objectives to reduce inequalities. These objectives are
general (both general and targeted) in seven countries, targeted in four
countries, and complementary in ﬁve countries.
To monitor participation (Fig. 2), most countries use socioeconomic
variables. All countries monitor participation by age and territory, and
half of them also include other variables, such as socio-economic level,
educational level and/or ethnicity/nationality. Moreover, 13 countries
have identiﬁed vulnerable populations that participate to a lesser extent
in their programmes (Fig. 2), with the deprived population and mi-
grant/ethnic minority groups being the population groups most com-
monly identiﬁed, followed by older women and those with a lower
level of education. On the other hand, 18 countries identiﬁed barriers
to participation (Fig. 2), with beliefs, knowledge and accessibility
being the barriers most commonly detected. Finally, 17 countries have
acted to tackle inequalities in participation. The majority of such inter-
ventions were performed in the period 2007–2012 — nine countries
performed no such intervention in 2012–2014 (Table 5). Interventions
directed to the general population were the most frequent. Examples
of interventions (Table 5) are: information strategies (e.g.: general in-
formation campaigns, informative materials adapted to the needs of
speciﬁc population groups, information sessions, community courses);
organisational changes (e.g.: establishment of population-based
screening programmes); accessibility improvements (e.g.: decrease in
transport barriers, removal of fees, facilitation of out-of-hours appoint-
ments, establishing mobile units in rural areas and targeting ethnic
communities); invitation strategies (e.g.: follow-up calls to non-atten-
dants); social participation mechanisms and empowerment (e.g.:or total target population 45–70 (entire population targeted in 2014).
vite women aged 50–68 years every two years. Therefore, the coverage of invitations and
lated using numbers from the year 2010 would not give a real picture on the invitational
expands gradually in ages 60–69 until 2016.
s of the federal states without adjustment for eligibility. Womenwith one of the following
2months, womenwith symptoms for breast cancer and women with breast cancer and in
ulation is not possible due to very strict data protection regulations.
The invitation is registered and paid by National Health Insurance Fund (NHIF) onlywhen
bers of screening tests.
Table 4
Inequalities in access to breast cancer screening programmes: individual cost, vulnerable populations not covered by the programme, objectives to tackle social inequalities in participation
(2010–2014).
Country Is the participation in the
programme free of charge?
Is there any vulnerable population not
covered by the programme?
Does the programme include objectives to tackle social inequalities in
participation?
Yes/No Yes/No Type of vulnerable population Yes/No Type of
approach
Content
Austria Yes No No
Belgiuma (3/3) Yes (3/3) Yes
(3/3)
Not health insured No (3/3)
Bulgaria Yes Yes Not health insured Not
reported
Croatia Yes Yes Without residence permits Yesb General Arise knowledge of target population by more
educational activities
Cyprus Yes Yes Without residence permits
Prisoners
No
Czech Republic Yes Yes Without residence permits Yes General To decrease inequalities in screening coverage across
age groups and regions by implementing individual
invitations and implement quality assurance
mechanisms
Denmark Yes No No
Estonia Yes Yes Not health insured Yes Targeted To reduce inequalities we have to include to
screenings also those groups who do not have
insurance
Finland Yes No Yes General To reduce social inequality inviting by a personal
letter
France Yes No Yes Complementary 1) To inform GPs, physicians and medical staff
working in prisons, local and national social
organisations, immigrant groups and NGOs.
2) To improve accessibility by mobile screening bus
Germany Yes Yes Without residence permits Yes General To send personal written invitation based on the data
provided by population registries
Hungary Yes No No
Ireland Yes No Yes Complementary To inform “hard to reach” target populations and to
address barriers of speciﬁc subgroups to increase
accessibility. Some of the initiatives include:
information sessions, community courses and the
development of information leaﬂets in different
formats and languages
Italy Yes Yes Without residence permits
Prisoners
Not registered in the basic
municipal register
Yesb Targeted To involve disadvantaged groups (included in the
Local Health Plan)
Latvia Yes Yes Without residence permits
Prisoners
Undergoing treatment at least
3 months at mental hospital
No
Lithuania Yes Yes Not health insured
Without residence permits
Prisoners
No
Luxembourg Yes No No
Malta Yes No Yes General The invitation includes an appointment date and time
for a mammogram
Netherlands Yes Yes Not registered in the basic
municipal register
Yes Complementary To regularly test and evaluate education and
communication materials also among low SES groups
Norway No No No
Poland Yes Yes Not health insured
Without residence permits
Prisoners
Not registered in the basic
municipal register
Yes General To improve participation inviting by a personal letter,
and educate the target population about cancer and
screening
Portugala (4/7) Yes
(4/4)
Yes
(2/4)
Not health insured No
(4/4)
Romaniab Yes No Yes Targeted To achieve access of Roma population and other
disadvantaged groups from rural and isolated areas
Sweden Yes Yes Without residence permits Yes General To invite every woman in the right age group with a
residence permit
Slovenia Yes Yes Not health insured Yes Targeted To screen women with no health insurance, too
Spaina (15/19) Yes
(15/15)
Yes
(4/15)
Without public health card
Prisoners
Yes
(8/15)
Complementary Free access and diagnosis, also for those who are not
entitled to assistance in the public health system
UKa (England) Yes No Yes Complementary The objective to tackle inequalities in screening comes
from the Public Health Outcome Framework of the
National Health System: “To improve and protect the
nation's health and wellbeing, and improve the health
of the poorest fastest”
a Response elaborated with regional data (number of regions responding/total of regions).
b Data available only for 2014.
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Participation periodically 
analysed according to 
socioeconomic variables 
(2010-2014)
Population groups 
identified that participate 
to a lesser extent than 
others (2010-2014)
Barriers to participation 
studied (2010-2014)
Interventions to tackle 
inequalities in 
participation (2007-2014)
Fig. 2.Monitoring, evaluating and tackling inequalities in participation (2007–2014).
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monitoring and research (e.g.: participation monitoring in speciﬁc geo-
graphic locations, studies of reasons for non-attendance).
4. Discussion
Population-based breast cancer screening is now in place in nearly
all EUmember states. By 2014, in 23out of 28member states, the rollout
of an organised or population-based programmewas complete (82.1%),
in 2 the rollout was ongoing (7.1% — Slovenia and Northern Region of
Portugal), 1 country was piloting a programme (Bulgaria), and another
was planning to pilot a programme (Romania). For the two remaining
countries (Greece and Slovakia), for which no data were provided, the
most recent international source of information on screening
programmes (von Karsa et al., 2008; Lerda et al., 2014) provided no ev-
idence that an organised breast cancer screening programme was in
place or planned, although some evidence exists for Greece (Simou et
al., 2011; Trigoni et al., 2008; Trigoni et al., 2011; Tsounis et al., 2014).
The present results are consistent with the ﬁndings in the Implementa-
tion Report (von Karsa et al., 2008). They show a positive trend towards
compliancewith the Council Recommendation and are encouraging, es-
pecially when considered together with the recent data on organised
breast cancer screening in non-EU Mediterranean countries (Giordano
et al., 2016), where such programmes are rare and do not meetinternational recommendations. In particular, only 4 out of the 25 coun-
tries with a programme in place do not cover the 50–69 age group,
whilst the eligible age in 7 countries extends above or below this age
threshold. It is worth noting the recent IARC viewpoint (Lauby-
Secretan et al., 2015), which suggests there is sufﬁcient evidence of
mortality reduction for women aged 70–74, whilst for women aged
45–49 the evidence is limited. Moreover, three countries employ a dif-
ferent invitation schedule, using baseline risk as deﬁned by breast den-
sity and/or speciﬁc age groups. In the Implementation Report there was
no evidence of tailored screening protocols in place in organised
programmes, which may reﬂect that research activity on tailored
screening is still ongoing (Paci and Giorgi Rossi, 2010).
Taking into account the overall results of the 20 countries/regions
that provided complete data for 2010 and 2014 (see Table 3, i.e. Austria,
Belgium— Brussels, Croatia, Cyprus, Estonia, Finland, France, Germany,
Ireland, Italy, Luxembourg, Latvia, the Netherlands, Norway, Poland,
Portugal, Spain, Sweden, Slovenia, England), mean coverage by invita-
tion increased by 3% (86.8% to 90.1%), and coverage by test by 4%
(48.3% to 52.6%). This increase seems to be mainly due to progress or
completion of rollout in Austria, Latvia, Italy, and Slovenia. Globally, cov-
erage by invitation and by test still seems to be improving slightly, de-
spite the austerity measures implemented in Europe over the last ﬁve
years. However, the large range observed for the indicators in different
countries (e.g. participation rate ranging from 8.3% to 84.8% in 2010 and
Table 5
Interventions to reduce inequalities in participation performed in the periods 2007–2012 and 2012–2014.
Country Objective Target Population Type of
intervention
Description of the intervention Outcomes
Austria
2007–2012 To increase participation
and inform the women in
the target population
General population Information General campaigns Not evaluated
2012–2014 To implement the
population-based screening
programme
General population Information Campaigns of general information in 4
languages
Evaluation ongoing
Bulgaria
2007–2012 No No No No No
2012–2014 Not reported Not reported Not reported Not reported Not reported
Czech Republic
2007–2012 To increase participation
and inform the women in
the target population
General population Information General campaigns Continuous increase in coverage by
examination
2012–2014 To reduce inequalities in
participation
General population:
45–70
Organisational
changes
Implemented a population-based
screening (by individual invitations)
13.4% participation in previously
unscreened women, overall decrease
inequalities to be evaluated
Estonia
2007–2012 To increase participation General population Accessibility
improvement
Decrease of transport barriers: make the
timetables mammography buses more
intense
Participation rise 15%
2012–2014 No No No No
France
2007–2012 To reduce inequalities and
increase participation
Vulnerable population
and Health professionals:
GPs medical, staff in
prisons, immigration
NGO, low income
population
Information,
social
participation
mechanism,
empowerment
Local initiatives and National campaigns:
actions in the National Cancer Plans
(2009–2013 and 2014–2019) were
dedicated to reduction of inequalities in
breast cancer screening
Increase of participation in the targeted
population
2012–2014 Continuity Continuity Continuity Continuity
Germany
2007–2012 To implement the
population based screening
programme
General population Information General campaigns Since 2009 fully implemented
programme, plenty of information
material, regular invitation of the entire
target population
2012–2014 Change in communication
and information strategies
towards enabling informed
decision rather than
increasing participation
General population Information Revision of most information material,
introduction of new information
material: video statements, information
ﬁlms, graphics, new internet presence
with speciﬁc portals for different
users-women, physicians, media,….
Nothing measured
Ireland
2007–2012 1) To inform about early
detection, prevention and
screening;
2) To address barriers of
speciﬁc subgroups to
increase accessibility;
3) To advocate on behalf of
all service users to ensure an
equitable service
General and vulnerable
population and Health
professionals:
community, voluntary
organisations, statutory
bodies, health
professionals and other
relevant agencies,
speciﬁc ‘hard to reach’
target populations
Information,
empowerment
General campaigns and speciﬁc
initiatives for ‘hard to reach’ targeted
populations: information sessions,
community courses, health fairs and
staffed displays.
Examples of social inclusion work
include, developing a language tool for
use by radiographers, organising
language and sign interpreters, the
development of materials in other
languages and formats
Speciﬁc ‘hard to reach’ targeted
populations have been directly reached
by health promotion teams.
Key messages on early detection and
prevention have been developed.
Our social inclusion work ensures that
these groups are given every
opportunity to access our services and
their speciﬁc needs understood and
responded to.
The development of low literacy
materials e.g. Breast Check pictorial
leaﬂet. On-going work and initiatives
with minority groups in training
community health workers,
appointment support for women and
low literacy support etc.
2012–2014 Identiﬁcation of groups with
low participation rates
Vulnerable population:
speciﬁc geographical area
Monitoring
and research,
empowerment
Monitoring of participation rates in
speciﬁc geographical locations
Various initiatives introduced for
reduced participation rates in this
locations
Health professionals such as Primary
Care Teams including General
Practitioners, Practice Nurses and Public
Health Nurses and also community
groups are asked to provide support in
creating awareness of the Breast
Screening Programme among their
patient population and encourage
women to attend for screening where
low rates of participation exist
(continued on next page)
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Table 5 (continued)
Country Objective Target Population Type of
intervention
Description of the intervention Outcomes
Italy
2007–2012 1) To analyse participation
by sub- groups (ethnic,
socio-economic groups).
2) To reduce barriers to
informed choice
Vulnerable population:
Ethnics/immigrants
groups
Research and
studies,
information
Study of barriers to design an
intervention
A National survey speciﬁc for People
coming from Countries with high
migration pressure has been carried out.
Several programmes have carried out
analysis of participation by
socio-economic status.
Several programmes adopt leaﬂets
translated into principal languages of
Countries with high migration pressure
2012–2014 No No No No
Luxembourg
2007–2012 To increase participation
rate
General population Information General campaigns Difﬁcult to measure.
2012–2014 No No No No
Malta
2007–2012 To implement the
population based screening
programme
General population Invitation
strategies
General campaign. Roll out of the national screening
programme
2012–2014 To increase the participation
rate
General population Information
Empowerment
1. Some projects have looked at motives
for non-attendance, by telephone
surveys and follow up calls; 2. data sets
have been cleaned up, and demographic
information made more reliable
Increase in attendance rate
Netherland
2007–2012 To raise informed decision
making of target population
General and Vulnerable
population:
speciﬁc geographical area
and speciﬁc
socioeconomic level
groups
Information,
monitoring
and research
1) Speciﬁc information for some groups
2) Monitoring of reasons for
non-participation
Continuous improvement of education
materials. Regular monitoring of reasons
for non-participation acting upon that
2012–2014 No No No No
Portugal
2007–2012 To promote participation,
analyse and reduce existing
barriers
General and vulnerable
population
Information,
accessibility
improvement
1) General campaigns
2) Provide transportation to women
with limited resources
Higher participation rate
2012–2014 No No No No
Poland
2007–2012 To promote participation General population Information,
invitation
strategies
1) General campaigns, information
material, lectures, and educational
events
2) Personal invitation by letter
Difﬁcult to measure
2012–2014 Continuity Continuity Continuity Continuity
Romania
2012–2014 1)To improve accessibility
2) To increase participation
Vulnerable population:
Roma and other
disadvantaged groups
Information,
accessibility
improvement
Regional information campaign with
mobile units and sanitary mediators
Expected Outcome: Up to 5000 tests in
disadvantaged groups in rural and
ethnic communities up to April 2016,
end of Project implementation
Sweden
2007–2012 1) To increase participation
2) To facilitate rebooking
3) To increase participation
General and vulnerable
population
Accessibility
improvement,
Invitation
Strategies,
Information
1) Political decision to take away the fee
2) Second invitation within one – two
weeks if they did not attend.
3) Speciﬁc information in several
languages focused on lower
socio-economic level; different phrasing
in invitation letter
Outcome: Increased participation
especially in areas with low
participation and among younger
women
2012–2014 No No No No
Slovenia
2007–2012 To rise participation rate
among no respondent
women
General population:
non-respondents
Invitation
strategies
Second and third invitation if they did
not attend
Third invitation with ﬁxed appointment
term not efﬁcient. Since then we send
only one additional invitation
2012–2014 To rise screening
participation rate
General population:
Women who did not
attend subsequent
screening interval after
being screened at least
once.
Monitoring
and research
Non-attendance questionnaire, still
on-going
It is effective to remind women about
screening after few years of being no
respondent – with motivation letter, not
with ﬁxed appointment for screening
Spain
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Table 5 (continued)
Country Objective Target Population Type of
intervention
Description of the intervention Outcomes
2007–2012 1)To improve accessibility
2) To empower population
in cancer prevention
3) To increase participation
and informed decision
making
General and vulnerable
population:
1) 1.1.rural and remote
population; 1.2.
psychiatric patients in
hospitals
2) Ethnic groups in high
vulnerable areas,
immigrant population
3) 3.1. general
population; 3.2.
vulnerable population
Accessibility
improvement,
Information,
Empowerment
1) 1.1.Mobile units, free transportation;
1.2.Accessibility for psychiatric patients
admitted in Hospitals
2) Training health agents from local
ethnic groups, action-participative
research
3) 3.1.General campaigns, 3.2.Meetings
with vulnerable population
1.1) Increase participation/participation
rates unchanged 1.2) Identiﬁcation of
speciﬁc needs
2) Community empowerment/Not
assessed
3) Improvement of informed
participation
2012–2014 No No No No
UK (England)
2007–2012 To increase participation General population Accessibility
improvement
Offer of out of hours appointment The highest attendance was observed in
the group offered an initial ofﬁce hour
appointment with the option to change
to out-of-hours (76.1% vs 73.3% for
standard ofﬁce hour, P2 0.001), with 7%
of invitation
2012–2014 No No No No
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European screening programmes — an issue that must be taken into
consideration by policy-makers.
It is widely accepted that European health care policies, such as ‘uni-
versal’ national health systems and ‘population-based’ cancer screening
programmes, promote equity. However, vulnerable populations have
been identiﬁed as being excluded from the target population (e.g.:
women without health insurance, women without residence permits,
and women in prison). According to the deﬁnition of target population
included in the European Guidelines (Perry et al., 2006), ‘all women eli-
gible to attend for screening on the basis of age and geographic location
(dictated by screening policy)’ shall be invited. This deﬁnition also spec-
iﬁes that ‘special groups such as institutionalised or minority groups’
should be included. It would therefore be advisable for European breast
cancer screening programmes to ensure that the deﬁnition of their tar-
get population is in accordance with the European Guidelines, including
that for vulnerable populations.
Monitoring participation is another quality indicator recommended
in the European Guidelines (Perry et al., 2006). Age and territory are the
most common variables used to analyse participation, but effort is need-
ed to also include variables related with ethnicity and socioeconomic
level in cancer screening registries. This study identiﬁed inequalities in
participation, with socially vulnerable groups showing a lower partici-
pation rate. These results are consistent with those of other studies
(Palència et al., 2010; Euler-Chelpin et al., 2008; Dolansky, 2006;
Maheswaran et al., 2006). Reducing social inequalities in cancer could
be achieved with different approaches, both general and targeted. The
general approach takes into account the whole population, and seeks
to reduce the difference in health between high, middle and low-in-
come groups by providing health opportunities equally across all socio-
economic strata. The targeted approach focuses only on people in the
poverty stratum. Both approaches are complementary and interdepen-
dent (Whitehead and Dahlgren, 2006). Interventions to tackle inequal-
ities with general and targeted approaches are therefore needed.
This study reports the implementation status of breast cancer
screening programmes in most EU countries. However, as the Council
Recommendation invited to maximise beneﬁts and minimise harms of
screening and to comply with quality assurance guidelines, our study
is limited to some extent by a lack of information on the quality of the
service actually provided by those countries. This is important,particularly in view of the debate on the undesirable effects of mam-
mography screening, such as overdiagnosis.
Despite continuous improvement in the implementation of breast
cancer screening programmes, it may be challenging in future to main-
tain the coverage achieved despite austerity, to reduce inequalities in
access, and to maximise the risk-beneﬁt ratio. Moreover, strategies to
reduce inequalities in cancer screening must be implemented. For this
to happen, the unequal distribution of barriers limiting access to screen-
ing among different socioeconomic and cultural groupsmust be further
analysed so that suitable interventions that improve access to good
quality screening may be developed.
5. Conclusion
Organised, population-based breast cancer screening programmes
based on routinemammograms are in place in most EUmember states.
However, there are still differences in the way breast cancer screening
programmes are implemented which could translate into cancer in-
equalities. Offering universal and free access to breast cancer screening
and implementing interventions to encourage participation by vulnera-
ble populations through information and invitation strategies as well as
social participation and empowerment mechanisms will be needed. In
the future, studies on the quality of the services provided will also be
necessary.
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